Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Transplant Reject Clear all
Recruiting Phase 1 Interventional

A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation

NCT06990711
View directory record Official record
Conditions
Antibody Mediated Rejection of Lung Transplant
Interventions
Siltuximab, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
St Louis, Missouri • Saint Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 24, 2026, 5:28 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRI

NCT04941573
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Hyperpolarized 129-Xenon (MagniXene) MRI of the lung
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Jul 24, 2026, 5:28 AM EDT
Recruiting No phase listed Observational

Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes

NCT06399302
View directory record Official record
Conditions
Lung Transplant; Complications, Lung Transplant; Infection or Inflammation, Lung Transplant Rejection, Lung Transplant Failure
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 24, 2026, 5:28 AM EDT
Recruiting Not applicable Interventional

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

NCT06538376
View directory record Official record
Conditions
Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion, Acute Rejection of Lung Transplant (Disorder), Airway Obstruction, Rib Fractures, Acute Copd Exacerbation, Asthma COPD, Pulmonary Embolism, Hemothorax, Pneumothorax, Mesothelioma, Diaphragmatic Paralysis
Interventions
Portable Dynamic Digital Radiography (DDR)
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 24, 2026, 5:28 AM EDT
Terminated Phase 2 Interventional Results available

Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)

NCT03473340
View directory record Official record
Conditions
Disorder Related to Lung Transplantation, Chronic Lung Allograft Dysfunction
Interventions
Pirfenidone Capsule, Placebo Capsule
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jul 24, 2026, 5:28 AM EDT
Completed No phase listed Observational

Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung

NCT01793246
View directory record Official record
Conditions
Lung Neoplasms, Disorder Related to Lung Transplantation
Interventions
probe based laser endomicroscopy (pCLE)
Device
Lead sponsor
Mauna Kea Technologies
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
9
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Jul 24, 2026, 5:28 AM EDT
Terminated No phase listed Observational

PET Assessment of Acute Lung Transplant Rejection

NCT02204202
View directory record Official record
Conditions
Lung Disease
Interventions
[18F]FDG, [18F]ISO-1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
19 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 24, 2026, 5:28 AM EDT
Recruiting Not applicable Interventional

Cryoprobe Biopsy and Chronic Rejection in Lung Transplant Recipients

NCT06824402
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Forceps Biopsy, Cryoprobe Biopsy
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 24, 2026, 5:28 AM EDT
Active, not recruiting Phase 2 Interventional

Advanced Immunoclinical Phenotyping of Rejection in Lung Transplant

NCT03697395
View directory record Official record
Conditions
Chronic Rejection of Lung Transplant
Interventions
Lung transplant recipient without MRI imaging, Lung transplant recipient with MRI imaging
Diagnostic Test · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jul 24, 2026, 5:28 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Lung Allograft Rejection Gene Expression Observational (LARGO) Study

NCT00751309
View directory record Official record
Conditions
Graft Rejection, Lung Disease
Interventions
Non-interventional
Other
Lead sponsor
XDx
Industry
Eligibility
Not listed
Enrollment
2,044 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Jul 24, 2026, 5:28 AM EDT
Completed No phase listed Observational

Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival

NCT00531921
View directory record Official record
Conditions
Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 70 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Ithaca, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Jul 24, 2026, 5:28 AM EDT
Completed No phase listed Observational

Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection

NCT03984747
View directory record Official record
Conditions
Transplant Rejection, Allograft Rejection, Complications
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
2 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
San Carlos, California • San Diego, California • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Jul 24, 2026, 5:28 AM EDT
Withdrawn Not applicable Interventional

Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation

NCT02395393
View directory record Official record
Conditions
Disorder Related to Lung Transplantation
Interventions
Alveoflex Confocal MiniprobeTM
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 22 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Jul 24, 2026, 5:28 AM EDT
Completed Phase 1 Interventional

Mesenchymal Stem Cell Therapy for Lung Rejection

NCT02181712
View directory record Official record
Conditions
Lung Transplant Reject, Bronchiolitis Obliterans
Interventions
Mesenchymal stem cell 0.5, Mesenchymal stem cell 1.0
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Jul 24, 2026, 5:28 AM EDT
Completed No phase listed Observational

Alveoscopy, Endoscopic Confocal Microscopy and Lung Rejection, Parenchymal Lung Diseases in Vivo

NCT01033201
View directory record Official record
Conditions
Lung Transplant
Interventions
Confocal imaging
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Jul 24, 2026, 5:28 AM EDT
Completed No phase listed Observational

Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation

NCT00528853
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Jul 24, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation

NCT03388008
View directory record Official record
Conditions
Lung Transplant Rejection, Antibody-mediated Rejection
Interventions
Belatacept, Tacrolimus, ATG, Mycophenolate Mofetil, Methylprednisolone, Prednisone
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
St Louis, Missouri • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2022 · Synced Jul 24, 2026, 5:28 AM EDT
Withdrawn Phase 4 Interventional

Macitentan in the Treatment of Organ Rejection After Lung Transplantation

NCT02893176
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
macitentan, placebo (for macitentan)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Jul 24, 2026, 5:28 AM EDT
Completed Phase 2 Interventional Results available

Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation

NCT02474927
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Carfilzomib
Drug
Lead sponsor
John F. McDyer, MD
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 24, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

NCT00105183
View directory record Official record
Conditions
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions
Placebo, EZ-2053, EZ-2053 5mg/kg
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 24, 2026, 5:28 AM EDT
Active, not recruiting No phase listed Observational

LAMBDA 002 (Lung Registry) Study

NCT05170425
View directory record Official record
Conditions
Lung Transplant Rejection
Interventions
Prospera
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
11
States / cities
California City, California • Chicago, Illinois • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 24, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

NCT06018766
View directory record Official record
Conditions
Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction, Lung Transplantation
Interventions
LAM-001, Placebo
Drug
Lead sponsor
Steven Hays, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 24, 2026, 5:28 AM EDT
Terminated Not applicable Interventional

Goal of Open Lung Ventilation in Donors

NCT03439995
View directory record Official record
Conditions
Brain Death, Organ Donation, Organ Transplant Failure or Rejection
Interventions
Open lung protective ventilation, Conventional ventilation
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Jul 24, 2026, 5:28 AM EDT
Completed No phase listed Observational

Clinical Trials in Organ Transplantation Extension Study

NCT04126746
View directory record Official record
Conditions
Lung Transplant Failure and Rejection
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Jul 24, 2026, 5:28 AM EDT